IN2014DN09050A - - Google Patents

Info

Publication number
IN2014DN09050A
IN2014DN09050A IN9050DEN2014A IN2014DN09050A IN 2014DN09050 A IN2014DN09050 A IN 2014DN09050A IN 9050DEN2014 A IN9050DEN2014 A IN 9050DEN2014A IN 2014DN09050 A IN2014DN09050 A IN 2014DN09050A
Authority
IN
India
Prior art keywords
site
dosing regimen
nerve block
prolonged
stx
Prior art date
Application number
Inventor
Sahadev Aramanethalgur Shankarappa
Daniel S Kohane
Original Assignee
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp filed Critical Childrens Medical Ct Corp
Publication of IN2014DN09050A publication Critical patent/IN2014DN09050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain such as hyperalgesia and/or allodynia for at least one week and preferably longer at the site and preferably the region (e.g. entire limb) where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX) preferably in combination with a corticosteroid preferably dexamethasone. In a preferred embodiment liposomes are included in the formulation as a controlled release system producing prolonged duration of block without systemic toxicity. As demonstrated by the examples encapsulating STX in a controlled release system such as liposomes preferably also including a corticosteroid and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity delays the onset of hyperalgesia.
IN9050DEN2014 2012-04-23 2013-04-23 IN2014DN09050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637156P 2012-04-23 2012-04-23
PCT/US2013/037838 WO2013163214A1 (en) 2012-04-23 2013-04-23 Formulations and methods for delaying onset of chronic neuropathic pain

Publications (1)

Publication Number Publication Date
IN2014DN09050A true IN2014DN09050A (en) 2015-05-22

Family

ID=48227582

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9050DEN2014 IN2014DN09050A (en) 2012-04-23 2013-04-23

Country Status (6)

Country Link
US (1) US9408846B2 (en)
EP (1) EP2841071A1 (en)
JP (1) JP2015514805A (en)
CN (1) CN104427987A (en)
IN (1) IN2014DN09050A (en)
WO (1) WO2013163214A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process
CN105919979B (en) * 2016-06-28 2019-07-02 国家海洋局第三海洋研究所 A kind of tetradoxin enteric sustained-release pellet, preparation method and applications
CN107115298A (en) * 2017-05-22 2017-09-01 黄海枫 A kind of TTX emulsio olei jecoris piscis
AU2018375002B2 (en) * 2017-12-01 2021-11-11 The Children's Medical Center Corporation Covalent anesthetic-polymer conjugates for prolonged local anesthesia
WO2019113184A1 (en) * 2017-12-06 2019-06-13 Children's Medical Center Corporation Nanoparticles for nerve penetration and uses thereof
KR101841654B1 (en) * 2017-12-19 2018-03-26 (주)나노스템 Composition and Method for Treating, relieving or Preventing Neuropathic Pain
CN117562869B (en) * 2023-05-05 2024-07-16 中南大学湘雅医院 Magnesium hydroxide nanoparticle for treating arthralgia, preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1111453A (en) 1993-07-01 1995-11-08 日本钢管株式会社 Arylsulfonamide derivative and pharmaceutical composition containing the same
US5776488A (en) * 1994-03-11 1998-07-07 Yoshitomi Pharmaceutical Industries, Ltd. Liposome preparation
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
WO2010093615A2 (en) 2009-02-10 2010-08-19 Tulane University Compounds, their syntheses, compositions, and methods to treat cancer
US20120034296A1 (en) 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity

Also Published As

Publication number Publication date
JP2015514805A (en) 2015-05-21
US20150079159A1 (en) 2015-03-19
EP2841071A1 (en) 2015-03-04
CN104427987A (en) 2015-03-18
WO2013163214A1 (en) 2013-10-31
US9408846B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
IN2014DN09050A (en)
MX2022003572A (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody.
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MY188139A (en) Sodium channel modulators for the treatment of pain
MY175800A (en) Combination treatment of cancer
MX2016009666A (en) Topical delivery of skin compositions having low ph.
MX360391B (en) Combinational liposome compositions for cancer therapy.
PH12020550341A1 (en) Niraparib formulations
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
WO2012148174A3 (en) Composition for topical application for preventing hair loss and stimulating hair growth
JOP20170091B1 (en) Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
EP4058190A4 (en) Compositions and methods for controlled delivery and protection of therapeutic agents
NZ711500A (en) Engineering a control drug release profile via liposome compositions in both aqueous and non-aqueous compartments
WO2012131341A3 (en) Tight junctions modulators
MX2015017879A (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase.
MX2020001428A (en) Compositions of grapiprant and methods for using the same.
EP4087602A4 (en) Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
MX2015017124A (en) Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy.
MX2009002985A (en) Formulations for therapeutic administration of thyroid stimulating hormone (tsh).
MX2019011749A (en) Reducing beta-catenin expression to potentiate immunotherapy.
BR112014018426A8 (en) COMPOSITION AND DEVICE FOR TRANSDERMAL ADMINISTRATION, AND METHOD FOR ADMINISTERING A PROGESTIN
SG11201808241WA (en) Composition for skin moisturization or skin whitening, containing pentacyclic triterpene caffeic acid esters
GR1008819B (en) Pharmaceutical composition comprising atomoxetine and method for the preparation thereof